The inflammatory response to surgery and trauma

Current Opinion in Critical Care

Volumn 12, Issue 4, 2006, Pages 325-332

  Kohl, Benjamin A ^a   Deutschman, Clifford S ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b C/o Dulles 781A/HUP ^*  (United States)

Author keywords

Catabolism; Cytokine; Inflammation; Stress; Stress response; Surgical complications

Indexed keywords

ALCOHOL; ANTINEOPLASTIC AGENT; CATECHOLAMINE; GLUCOSE; GLUTAMINE; GROWTH HORMONE; HYDROCORTISONE; INSULIN; LIOTHYRONINE; OXYGEN; PROLACTIN; RECOMBINANT GROWTH HORMONE; STEROID; TESTOSTERONE; THYROTROPIN; THYROXINE; VASOPRESSIN;

ALCOHOL ABUSE; ASPLENIA; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CARDIOVASCULAR SYSTEM; CATABOLISM; CATECHOLAMINE RELEASE; CLINICAL TRIAL; CLONAL ANERGY; COMA; COMORBIDITY; CRITICAL ILLNESS; CYTOKINE RELEASE; DRUG FATALITY; ELECTIVE SURGERY; ENDOCRINE DISEASE; ENDOCRINE SYSTEM; ENERGY EXPENDITURE; FEVER; GLUCAGON RELEASE; GLUCONEOGENESIS; GROWTH HORMONE RELEASE; HEART INFARCTION; HEART OUTPUT; HUMAN; HYDROCORTISONE RELEASE; HYPERGLYCEMIA; HYPERMETABOLISM; HYPOGONADOTROPIC HYPOGONADISM; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHERMIA; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INJURY; INSULIN RELEASE; LEUKOCYTE; LEUKOCYTOSIS; LEUKOPENIA; LIOTHYRONINE BLOOD LEVEL; LUNG MINUTE VOLUME; LYMPHOCYTE; MALNUTRITION; MYXEDEMA; OXYGEN CONSUMPTION; OXYGENATION; PATHOPHYSIOLOGY; POSTOPERATIVE INFLAMMATION; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR; STRESS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T LYMPHOCYTE; TACHYCARDIA; TESTOSTERONE BLOOD LEVEL; TH1 CELL; TH2 CELL; THYROXINE BLOOD LEVEL; VASOPRESSIN RELEASE; WOUND HEALING;

HUMANS; STRESS; STRESS, PHYSIOLOGICAL; SURGICAL PROCEDURES, OPERATIVE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; WOUNDS AND INJURIES;

EID: 33746077716     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/01.ccx.0000235210.85073.fc     Document Type: Review

References (71)

1. Cuthbertson DP. Observations on the disturbances of metabolism produced by injury to the limbs. Q J Med 1932; 1:233-244.
2. Cuthbertson D, Tilstone WT. Metabolism during the postinjury period. Adv Clin Chem 1969; 12:1-55.
3. Moore FD, Olsen KH, McMurrey JD. The body cell mass and its supporting environment. Philadelphia: WB Saunders; 1978.
4. Cerra FB, Siegel JH, Border JR, et al. Correlations between metabolic and cardiopulmonary measurements in patients after trauma, general surgery and sepsis. J Trauma 1979; 19:621-629.
5. Clowes GHA, O'Donnell TF, Blockburn GL, et al. Energy metabolism and proteolysis in traumatized and septic man. Surg Clin North Am 1976; 56:1169-1184.
6. Monk DN, Plank LD, Franch-Arcas G, et al. Sequential changes in the metabolic response in critically injured patients during the first 25 days after blunt trauma. Ann Surg 1996; 223:395-405.
7. Russell JA, Ronco JJ, Lockhat D, et al. Oxygen delivery and consumption and ventricular preload are greater in survivors than in non survivors of the adult respiratory distress syndrome. Am Rev Respir Dis 1990; 141:659-665.
8. Shoemaker WC, Montgomery ES, Kaplan E, et al. Physiologic patterns in surviving and nonsurviving shock patients. Arch Surg 1973; 106:630-636.
9. Hayes MA, Timmins AC, Yau EHS, et al. Oxygen transport patterns in patients with sepsis syndrome or septic shock: Influence of treatment and relationship to outcome. Crit Care Med 1997; 25:926-936.
10. Hayes MA, Yau EHS, Timmins AC, et al. Response of critically ill patients to treatment aimed at achieving supranormal oxygen delivery and consumption: relationship to outcome. Chest 1993; 103:886-895.
11. Hunt TK, Knighton DR, Thakral KK, et al. Studies on inflammation and wound healing: angiogenesis and collagen synthesis stimulated in vivo by resident and activated wound macrophages. Surgery 1984; 96:48-54.
12. Frank S, Hubner G, Breier G, et al. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. J Biol Chem 1995; 270:12607-12613.
13. Shoemaker WC, Czer LSC. Evaluation of the biologic importance of various haemodynamic and oxygen transport variables. Crit Care Med 1979; 24:517-524.
14. Shoemaker WC, Appel PL, Kram HB, et al. Prospective trial of supranormal values of survivors as therapeutic goals in high risk surgical patients. Chest 1988; 94:1176-1186.
15. Rivers E, Nguyen B, Havstad S, et al. Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377.
16. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care. Crit Care Med 2001; 29:1303-1310.
17. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. American College of Chest Physicians, Society of Critical Care Medicine Consensus Conference Committee. Chest 1992; 101:1644-1655.
18. Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554.
19. Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time? Crit Care Med 1998; 26:2078-2086.
20. Orbach S, Weiss YG, Deutschman CS. Care of the patient with sepsis or the systemic inflammatory response syndrome. In: Murray MJ, Coursin DB, Pearl RG, Prough DS, editors. Critical care medicine: perioperative management. Philadelphia: Lippincott-Raven Publishers; 2002. pp. 601-615.
21. Clemens MG, Chaudry IH, Daigneau N, et al. Insulin resistance and depressed gluconeogenic capability during early hyperglycemic sepsis. J Trauma 1979; 24:701-708.
22. Deutschman CS, De Maio A, Clemens MG. Sepsis-induced attenuation of glucagons and 8Br-cAMP modulation of phosphor enol pyruvate carboxykinase gene. Am J Physiol 1995; 269:R584-R591.
23. Breslow MJ, Miller CF, Parker SD, et al. Effect of vasopressors on organ blood flow during endotoxin shock in pigs. Am J Physiol 1987; 252:H291-H300.
24. Ghosh S, Liu MS. Decrease in adenylate cyclase activity in dog livers during endotoxic shock. Am J Physiol 1983; 245:R737-R742.
25. Trzeciak S, Dellinger RP, Abate N, et al. Translating research to clinical practice: a 1-year experience with implementing early goal-directed therapy for septic shock in the emergency department. Chest 2006; 129:225-232. This is a real-world, more contemporary approach to early goal-directed therapy than that of [15]. The authors conducted a retrospective cohort analysis at an academic medical center implementing early goal-directed therapy at presentation and for 6 h. End points of resuscitation were reached in 20/22 cases.
26. Haitsma JJ, Lachmann B. Lung protective ventilation in ARDS: the open lung maneuver. Minerva Anestesiol 2006; 72:117-132. This is a very nice review of various lung protective strategies with emphasis on physiologic rationale.
27. Tao W, Deyo DJ, Traber DL, et al. Hemodynamic and cardiac contractile function during sepsis caused by cecal ligation and puncture in mice. Shock 2004; 21:31-37.
28. Lee HT, Gallos G, Nasr SH, Emala CW. A1 adenosine receptor activation inhibits inflammation, necrosis, and apoptosis after renal ischemia-reperfusion injury in mice. J Am Soc Nephrol 2004; 15:102-111.
29. Godin PJ, Buchman TG. Uncoupling of biological oscillators: a complementary hypothesis concerning the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 1996; 24:1107-1116.
30. Buchman T. The community of the self. Nature 2002; 420:246-251.
31. Buchman TG, Cobb JP, Lapedes AS, Kepler TB. Complex systems analysis: a tool for shock research. Shock 2001; 16:248-251.
32. Beishuizen A, Thijs LG, Haanen C, et al. Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness. J Clin Endocrinol Metab 2001; 86:2811-2816.
33. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2004; 348:138-150.
34. Ayala A, O'Neill PJ, Uebele SA, et al. Mechanism of splenic immunosuppression during sepsis: key role of Kupffer cell mediators. J Trauma 1997; 42:882-888.
35. Oberholzer A, Oberholtzer C, Moldawer LL. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 2001; 16:83-96.
36. Shelley O, Murphy T, Paterson H, et al. Interaction between the innate and adaptive immune systems is required to survive sepsis and control inflammation after injury. Shock 2003; 20:123-129.
37. Venet F, Bohe J, Debard AL, et al. Both percentage of gammadelta T lymphocytes and CD3 expression are reduced during septic shock. Crit Care Med 2005; 33:2836-2840. A well designed study better elucidating the mechanism of sepsis-induced immunosuppression. The investigators describe not only decreased expression of histocompatibility locus antigen direct repeat (HLA-DR) but a reduced CD3 expression, which may help explain poor antigen presentation in patients with septic shock.
38. Van den Berghe G, de Zegher F, Bouillon R. Acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocrinol Metab 1998; 83:1827-1834.
39. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402:656-660.
40. Ross R, Miell J, Freeman E, et al. Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-1. Clin Endocrinol 1991; 35:47-54.
41. Hermansson M, Wickelgren RB, Hammerqvist F, et al. Measurement of human growth hormone receptor messenger ribonucleic acid by a quantitative polymerase chain reaction-based assay: demonstration of reduced expression after elective surgery. J Clin Endocrinol Metab 1997; 82:421-428.
42. Bentham J, Rodriguez-Arnao J, Ross RJ. Acquired growth hormone resistance in patients with hypercatabolism. Horm Res 1993; 40:87-91.
43. Timmins AC, Cotterill AM, Cwyfan Hughes SC, et al. Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and -II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein-3 protease. Crit Care Med 1996; 24:1460-1466.
44. Van den Berghe G, Baxter RC, Weekers F, et al. A paradoxical gender dissociation within the growth hormone, insulin-like growth factor I axis during protracted critical illness. J Clin Endocrinol Metab 2000; 85:183-192.
45. Van den Berghe G. Endocrine evaluation of patients with critical illness. Endocrinol Metab Clin N Am 2003; 32:385-410.
46. Van den Berghe G, de Zegher F, Bowers CY, et al. Pituitary responsiveness to growth hormone (GH) releasing hormone, GH-releasing peptide-2, and thyrotropin releasing hormone in critical illness. Clin Endocrinol 1996; 45:341-351.
47. Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341:785-792.
48. Biolo G, Iscra F, Toigo G, et al. Effects of growth hormone administration on skeletal muscle glutamine metabolism in severely traumatized patients: preliminary report. Clin Nutr 1997; 16:89-91.
49. Chopra IJ, Huang TS, Beredo A, et al. Evidence for an inhibitor of extrathyroidal conversion of thyroxine to 3,5,3′-triiodothyronine in sera of patients with non-thyroidal illness. J Clin Endocrinol Metab 1985; 60:666-672.
50. Bacci V, Schussler GC, Kaplan TB. The relationship between serum triiodothyronine and thyrotropin during systemic illness. J Clin Endocrinol Metab 1982; 54:1229-1235.
51. Rothwell PM, Lawler PG. Prediction of outcome in intensive care patients using endocrine parameters. Crit Care Med 1995; 23:78-83.
52. Fliers E, Wieringa WM, Swaab DF. Physiological and pathophysiological aspects of thyrotropin-releasing hormone gene expression in the human hypothalamus. Thyroid 1998; 8:921-928.
53. Peeters RP, Wouters PJ, Kaptein E, et al. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab 2003; 88:3202-3211.
54. Brent GA, Hershman JM. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentrations. J Clin Endocrinol Metab 1986; 63:1-7.
55. Van den Berghe G, Weekers F, Baxter RC, et al. Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness. J Clin Endocrinol Metab 2001; 86:3217-3226.
56. Klibanski A, Beitens IZ, Badger TM, et al. Reproductive function during fasting in man. J Clin Endocrinol Metab 1981; 53:258-266.
57. Wang C, Chan V, Yeung RTT. Effect of surgical stress on pituitary-testicular function. Clin Endocrinol 1978; 9:255-266.
58. Wang C, Chan V, Tse TF, et al. Effect of acute myocardial infarction on pituitary testicular function. Clin Endocrinol 1978; 9:249-253.
59. Van den Berghe G, de Zegher F, Lauwers P, et al. Luteinizing hormone secretion and hypoandrogenemia in critically ill men: effect of dopamine. Clin Endocrinol 1994; 41:563-569.
60. Devins SS, Miller A, Herndon BL, et al. Effects of dopamine on T-lymphocyte proliferative responses and serum prolactin concentrations in critically ill patients. Crit Care Med 1992; 263:9682-9685.
61. Van der Meer MJ, Sweep CG, Pesman GJ, et al. Synergism between IL-1 beta and TNF-alpha on the activity of the pituitary-adrenal axis and on food intake of rats. Am J Physiol 1995; 268:E551-E557.
62. Perlstein RS, Whitnall MH, Abrams JS, et al. Synergistic roles of interleukin-6, interleukin-1, and tumor necrosis factor in the adrenocorticotropin response to bacterial lipopolysaccharide in vivo. Endocrinology 1993; 132:946-952.
63. Lyson K, McCann SM. Induction of adrenocorticotropic hormone release by interleukin-6 in vivo and in vitro. Ann NY Acad Sci 1992; 650:182-185.
64. Vermes I, Beishuizen A. The hypothalamic-pituitary-adrenal response to critical illness. Best Pract Res Clin Endocrinol Metab 2001; 15:495-511.
65. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871.
66. Gonzales H, Nardi O, Annane D. Relative adrenal failure in the ICU: an identifiable problem requiring treatment. Crit Care Clin 2006; 22:105-118. This is an outstanding review on the current understanding of critical care-induced relative adrenal insufficiency.
67. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95:1122-1125.
68. Malay MB, Ashton RC Jr, Landry DW, et al. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999; 47:699-703.
69. Robin JK, Oliver JA, Landry DW. Vasopressin deficiency in the syndrome of irreversible shock. J Trauma 2003; 54:S149-S154.
70. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345:588-595.
71. Jochberger S, Mayr VD, Luckner G, et al. Serum vasopressin concentrations in critically ill patients. Crit Care Med 2006; 34:293-299. An intriguing study suggesting that the vasopressinergic system is likely more complex than previously thought. No correlation was noted between serum arginine vasopressin concentrations and hemodynamic variables.